Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results.

Facchini G, Rossetti S, Berretta M, Cavaliere C, Scagliarini S, Vitale MG, Ciccarese C, Di Lorenzo G, Palesandro E, Conteduca V, Basso U, Naglieri E, Farnesi A, Aieta M, Borsellino N, La Torre L, Iovane G, Bonomi L, Gasparro D, Ricevuto E, De Tursi M, De Vivo R, Lo Re G, Grillone F, Marchetti P, De Vita F, Scavelli C, Sini C, Pisconti S, Crispo A, Gebbia V, Maestri A, Galli L, De Giorgi U, Iacovelli R, Buonerba C, Cartenì G, D'Aniello C.

J Transl Med. 2019 Aug 29;17(1):296. doi: 10.1186/s12967-019-2047-4.

2.

Poor outcome for patients with gastric cancer and lung metastases treated with ramucirumab and paclitaxel.

Roviello G, Corona SP, Multari AG, Petrioli R, Rosellini P, Aieta M.

Anticancer Drugs. 2019 Aug;30(7):e0789. doi: 10.1097/CAD.0000000000000789.

PMID:
31305296
3.

Is there still a place for vinorelbine in advanced metastatic castration resistant prostate cancer?

Roviello G, Corona SP, Conca R, Petrioli R, Rosellini P, Bonetta A, Aieta M.

Medicine (Baltimore). 2019 Jun;98(26):e16249. doi: 10.1097/MD.0000000000016249.

4.

Anti-PD-1 versus anti-PD-L1 therapy in patients with pretreated advanced non-small-cell lung cancer: a meta-analysis.

Tartarone A, Roviello G, Lerose R, Roudi R, Aieta M, Zoppoli P.

Future Oncol. 2019 Jul;15(20):2423-2433. doi: 10.2217/fon-2018-0868. Epub 2019 Jun 25.

PMID:
31237152
5.

The influence of prior ramucirumab treatment on the clinical activity of FOLFIRI as third-line therapy in patients with metastatic gastric Cancer.

Roviello G, Petrioli R, Rosellini P, Multari AG, Conca R, Paganini G, Chiriacò G, Aieta M.

Invest New Drugs. 2019 Jun;37(3):524-530. doi: 10.1007/s10637-019-00725-3. Epub 2019 Jan 28.

PMID:
30687871
6.

Influence of Age and the Gleason Score in the Choice of Novel Hormonal Therapies Before and After Chemotherapy.

Roviello G, Corona SP, Aieta M, Roudi R.

Cancer Biother Radiopharm. 2019 Apr;34(3):141-146. doi: 10.1089/cbr.2018.2702. Epub 2019 Jan 8.

PMID:
30620216
7.

Pain predicts overall survival in men with metastatic castration-resistant prostate cancer treated with radium-223.

Roviello G, Gallicchio R, Bozza G, Rodriquenz MG, Aieta M, Storto G.

Onco Targets Ther. 2018 Dec 17;12:9-13. doi: 10.2147/OTT.S174206. eCollection 2019.

8.

Corticosteroid switch in heavily pre-treated castration-resistant prostate cancer patients progressed on abiraterone acetate plus prednisone.

Roviello G, Petrioli R, Bonetta A, Conca R, Rodriquenz MG, Aieta M.

Invest New Drugs. 2018 Dec;36(6):1110-1115. doi: 10.1007/s10637-018-0685-7. Epub 2018 Oct 22.

PMID:
30345466
9.

Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡.

Conte P, Frassoldati A, Bisagni G, Brandes AA, Donadio M, Garrone O, Piacentini F, Cavanna L, Giotta F, Aieta M, Gebbia V, Molino A, Musolino A, Ferro A, Maltoni R, Danese S, Zamagni C, Rimanti A, Cagossi K, Russo A, Pronzato P, Giovanardi F, Moretti G, Lombardo L, Schirone A, Beano A, Amaducci L, Bajardi EA, Vicini R, Balduzzi S, D'Amico R, Guarneri V; Reader study level-I and level-II Groups.

Ann Oncol. 2018 Dec 1;29(12):2328-2333. doi: 10.1093/annonc/mdy414.

PMID:
30219886
10.

Adjuvant treatment for EGFR-mutated non-small cell lung cancer: do we have a major breakthrough?

Roviello G, Imperatori M, Aieta M, Sollitto F, Landriscina M.

J Thorac Dis. 2018 Jul;10(Suppl 18):S2114-S2118. doi: 10.21037/jtd.2018.06.114. No abstract available.

11.

Lower urinary tract infections from external beam radiation therapy in prostate cancer: A single institution experience.

Roviello G, Generali D, Aieta M, Bonetta A.

Rep Pract Oncol Radiother. 2018 Jul-Aug;23(4):298-299. doi: 10.1016/j.rpor.2018.06.001. Epub 2018 Jul 17.

12.

Current status of androgen receptor-splice variant 7 inhibitor niclosamide in castrate-resistant prostate-cancer.

Sobhani N, Generali D, D'Angelo A, Aieta M, Roviello G.

Invest New Drugs. 2018 Dec;36(6):1133-1137. doi: 10.1007/s10637-018-0653-2. Epub 2018 Aug 7. Review.

PMID:
30083960
13.

Association between ramucirumab-related hypertension and response to treatment in patients with metastatic gastric cancer.

Roviello G, Corona SP, Multari AG, Paganini G, Chiriacò G, Conca R, Petrioli R, Generali D, Rosellini P, Aieta M.

Oncotarget. 2018 Apr 27;9(32):22332-22339. doi: 10.18632/oncotarget.24900. eCollection 2018 Apr 27.

14.

Is there a role for immunotherapy in malignant pleural mesothelioma?

Tartarone A, Lerose R, Aieta M.

Med Oncol. 2018 May 29;35(7):98. doi: 10.1007/s12032-018-1156-x. Review.

PMID:
29845408
15.

Docetaxel, oxaliplatin, 5FU, and trastuzumab as first-line therapy in patients with human epidermal receptor 2-positive advanced gastric or gastroesophageal junction cancer: Preliminary results of a phase II study.

Roviello G, Petrioli R, Nardone V, Rosellini P, Multari AG, Conca R, Aieta M.

Medicine (Baltimore). 2018 May;97(20):e10745. doi: 10.1097/MD.0000000000010745.

16.

The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale).

Guida M, Tommasi S, Strippoli S, Natalicchio MI, De Summa S, Pinto R, Cramarossa A, Albano A, Pisconti S, Aieta M, Ridolfi R, Azzariti A, Guida G, Lorusso V, Colucci G.

BMC Cancer. 2018 May 10;18(1):552. doi: 10.1186/s12885-018-4479-2.

17.

Lenvatinib for the treatment of renal cell carcinoma.

Roviello G, Corona SP, Bozza G, Aieta M, Generali D, Rodriquenz MG, Mileo AM, Imperatori M, Ianza A, Conca R, Sobhani N.

Expert Opin Investig Drugs. 2018 May;27(5):507-512. doi: 10.1080/13543784.2018.1472235. Epub 2018 May 14. Review.

PMID:
29718721
18.

Uncommon frame-shift exon 19 EGFR mutations are sensitive to EGFR tyrosine kinase inhibitors in non-small cell lung carcinoma.

Improta G, Zupa A, Natalicchio MI, Sisinni L, Marinaccio A, Bozza G, Vita G, Aieta M, Landriscina M.

Med Oncol. 2018 Jan 31;35(3):28. doi: 10.1007/s12032-018-1078-7.

PMID:
29387949
19.

Liquid biopsy for monitoring anaplastic lymphoma kinase inhibitors in non-small cell lung cancer: two cases compared.

Manicone M, Scaini MC, Rodriquenz MG, Facchinetti A, Tartarone A, Aieta M, Zamarchi R, Rossi E.

J Thorac Dis. 2017 Oct;9(Suppl 13):S1391-S1396. doi: 10.21037/jtd.2017.08.151. Review.

20.

Molecular characterization and prognostic significance of circulating tumor cells in patients with non-small cell lung cancer.

Tartarone A, Lerose R, Rodriquenz MG, Mambella G, Calderoni G, Bozza G, Aieta M.

J Thorac Dis. 2017 Oct;9(Suppl 13):S1359-S1363. doi: 10.21037/jtd.2017.07.80. Review.

21.

Progress and challenges in the treatment of small cell lung cancer.

Tartarone A, Giordano P, Lerose R, Rodriquenz MG, Conca R, Aieta M.

Med Oncol. 2017 Jun;34(6):110. doi: 10.1007/s12032-017-0966-6. Epub 2017 Apr 29. Review.

PMID:
28456992
22.

Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone.

Conteduca V, Caffo O, Lolli C, Aieta M, Scarpi E, Bianchi E, Maines F, Schepisi G, Salvi S, Massari F, Carrozza F, Veccia A, Chiuri VE, Campadelli E, Facchini G, De Giorgi U.

Prostate. 2017 Jun;77(9):1012-1019. doi: 10.1002/pros.23357. Epub 2017 Apr 20.

PMID:
28429372
23.

TRAP1 protein signature predicts outcome in human metastatic colorectal carcinoma.

Maddalena F, Simeon V, Vita G, Bochicchio A, Possidente L, Sisinni L, Lettini G, Condelli V, Matassa DS, Li Bergolis V, Fersini A, Romito S, Aieta M, Ambrosi A, Esposito F, Landriscina M.

Oncotarget. 2017 Mar 28;8(13):21229-21240. doi: 10.18632/oncotarget.15070.

24.

The evolving landscape in advanced penile cancer.

Buonerba C, Di Lorenzo G, Calderoni G, Ferro M, Perri F, Lombardi L, Ardito R, Federico P, Placido S, Aieta M.

Future Sci OA. 2015 Nov 1;1(3):FSO9. doi: 10.4155/fso.15.7. eCollection 2015 Nov. No abstract available.

25.

Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone.

Lolli C, Caffo O, Scarpi E, Aieta M, Conteduca V, Maines F, Bianchi E, Massari F, Veccia A, Chiuri VE, Facchini G, De Giorgi U.

Front Pharmacol. 2016 Oct 13;7:376. eCollection 2016.

26.

The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma: a systematic review.

Di Lorenzo G, De Placido S, Pagliuca M, Ferro M, Lucarelli G, Rossetti S, Bosso D, Puglia L, Pignataro P, Ascione I, De Cobelli O, Caraglia M, Aieta M, Terracciano D, Facchini G, Buonerba C, Sonpavde G.

Expert Opin Biol Ther. 2016 Nov;16(11):1387-1401. Epub 2016 Aug 5.

PMID:
27463642
27.

Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.

Lolli C, Basso U, Derosa L, Scarpi E, Sava T, Santoni M, Crabb SJ, Massari F, Aieta M, Conteduca V, Maruzzo M, La Russa F, Wheater M, Berardi R, Galli L, De Giorgi U.

Oncotarget. 2016 Aug 23;7(34):54564-54571. doi: 10.18632/oncotarget.10515.

28.

Monitoring and Characterization of Circulating Tumor Cells (CTCs) in a Patient With EML4-ALK-Positive Non-Small Cell Lung Cancer (NSCLC).

Aieta M, Facchinetti A, De Faveri S, Manicone M, Tartarone A, Possidente L, Lerose R, Mambella G, Calderone G, Zamarchi R, Rossi E.

Clin Lung Cancer. 2016 Sep;17(5):e173-e177. doi: 10.1016/j.cllc.2016.05.002. Epub 2016 May 18. No abstract available.

PMID:
27397482
29.

Possible applications of circulating tumor cells in patients with non small cell lung cancer.

Tartarone A, Rossi E, Lerose R, Mambella G, Calderone G, Zamarchi R, Aieta M.

Lung Cancer. 2017 May;107:59-64. doi: 10.1016/j.lungcan.2016.05.027. Epub 2016 May 31. Review.

PMID:
27339469
30.

Somatostatin Analog Therapy in Small Cell Lung Cancer.

Tartarone A, Lerose R, Aieta M.

Semin Nucl Med. 2016 May;46(3):239-42. doi: 10.1053/j.semnuclmed.2015.12.004. Review.

PMID:
27067504
31.

Evaluation of Social Support, Quality of Life, and Body Image in Women with Breast Cancer.

Spatuzzi R, Vespa A, Lorenzi P, Miccinesi G, Ricciuti M, Cifarelli W, Susi M, Fabrizio T, Ferrari MG, Ottaviani M, Giulietti MV, Merico F, Aieta M.

Breast Care (Basel). 2016 Feb;11(1):28-32. doi: 10.1159/000443493. Epub 2016 Feb 3.

32.

Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer.

Veccia A, Caffo O, De Giorgi U, Di Lorenzo G, Ortega C, Scognamiglio F, Aieta M, Facchini G, Mansueto G, Mattioli R, Procopio G, Zagonel V, D'Angelo A, Spizzo G, Bortolus R, Donini M, Lo Re G, Massari F, Vicario G, Zucali PA, Alesini D, Bonetti A, Mucciarini C, Nicodemo M, Berruti A, Fratino L, Lodde M, Messina C, Perin A, Santini D, Sava T, Tucci M, Basso U, Maines F, Burgio LS, Galligioni E.

Future Oncol. 2016 Feb;12(4):493-502. doi: 10.2217/fon.15.302. Epub 2016 Jan 18.

PMID:
26776493
33.

Crizotinib-induced cardiotoxicity: the importance of a proactive monitoring and management.

Tartarone A, Gallucci G, Lazzari C, Lerose R, Lombardi L, Aieta M.

Future Oncol. 2015;11(14):2043-8. doi: 10.2217/fon.15.47. Review. Erratum in: Future Oncol. 2015 Sep;11(18):2612.

PMID:
26198834
34.

Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study.

Antonuzzo L, Giommoni E, Pastorelli D, Latiano T, Pavese I, Azzarello D, Aieta M, Pastina I, Di Fabio F, Bertolini A, Corsi DC, Mogavero S, Angelini V, Pazzagli M, Di Costanzo F.

World J Gastroenterol. 2015 Jun 21;21(23):7281-8. doi: 10.3748/wjg.v21.i23.7281.

35.

How can we improve prognostic models in renal cell carcinoma?

Buonerba C, Ferro M, Perri F, Calderoni G, Mambella P, Giordano P, Piscitelli P, Montanaro V, Aieta M, Di Lorenzo G.

Expert Opin Pharmacother. 2015 Jun;16(9):1281-3. doi: 10.1517/14656566.2015.1046838.

PMID:
26001179
36.

When crizotinib-induced bradycardia becomes symptomatic: role of concomitant drugs.

Gallucci G, Tartarone A, Lombardi L, Aieta M.

Expert Rev Anticancer Ther. 2015;15(7):761-3. doi: 10.1586/14737140.2015.1045493. Epub 2015 May 11.

PMID:
25961872
37.

Clinical outcomes in a contemporary series of "young" patients with castration-resistant prostate cancer who were 60 years and younger.

Caffo O, Ortega C, Di Lorenzo G, Sava T, De Giorgi U, Cavaliere C, Macrini S, Spizzo G, Aieta M, Messina C, Tucci M, Lodde M, Mansueto G, Zucali PA, Alesini D, D'Angelo A, Massari F, Morelli F, Procopio G, Ratta R, Fratino L, Lo Re G, Pegoraro MC, Zustovich F, Vicario G, Ruatta F, Federico P, La Russa F, Burgio SL, Maines F, Veccia A, Galligioni E.

Urol Oncol. 2015 Jun;33(6):265.e15-21. doi: 10.1016/j.urolonc.2015.02.016. Epub 2015 Apr 20.

PMID:
25907622
38.

The epidermal growth factor receptors as biological targets in penile cancer.

Di Lorenzo G, Buonerba C, Ferro M, Calderoni G, Bozza G, Federico P, Tedesco B, Ruggieri V, Aieta M.

Expert Opin Biol Ther. 2015 Apr;15(4):473-6. doi: 10.1517/14712598.2015.993377. Epub 2014 Dec 11.

PMID:
25496291
39.

Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study.

Caffo O, De Giorgi U, Fratino L, Alesini D, Zagonel V, Facchini G, Gasparro D, Ortega C, Tucci M, Verderame F, Campadelli E, Lo Re G, Procopio G, Sabbatini R, Donini M, Morelli F, Sartori D, Zucali P, Carrozza F, D'Angelo A, Vicario G, Massari F, Santini D, Sava T, Messina C, Fornarini G, La Torre L, Ricotta R, Aieta M, Mucciarini C, Zustovich F, Macrini S, Burgio SL, Santarossa S, D'Aniello C, Basso U, Tarasconi S, Cortesi E, Buttigliero C, Ruatta F, Veccia A, Conteduca V, Maines F, Galligioni E.

Eur Urol. 2015 Jul;68(1):147-53. doi: 10.1016/j.eururo.2014.10.014. Epub 2014 Oct 25.

PMID:
25457020
40.

Natural history of malignant bone disease in hepatocellular carcinoma: final results of a multicenter bone metastasis survey.

Santini D, Pantano F, Riccardi F, Di Costanzo GG, Addeo R, Guida FM, Ceruso MS, Barni S, Bertocchi P, Marinelli S, Marchetti P, Russo A, Scartozzi M, Faloppi L, Santoni M, Cascinu S, Maiello E, Silvestris F, Tucci M, Ibrahim T, Masi G, Gnoni A, Comandone A, Fazio N, Conti A, Imarisio I, Pisconti S, Giommoni E, Cinieri S, Catalano V, Palmieri VO, Infante G, Aieta M, Trogu A, Gadaleta CD, Brunetti AE, Lorusso V, Silvestris N.

PLoS One. 2014 Aug 29;9(8):e105268. doi: 10.1371/journal.pone.0105268. eCollection 2014.

41.

Carboplatin plus etoposide in heavily pretreated castration-resistant prostate cancer patients.

Buonerba C, Federico P, Bosso D, Puglia L, Policastro T, Izzo M, Perri F, Vittoria Scarpati GD, Ferro M, Cobelli OD, De Placido S, Aieta M, Imbimbo C, Longo N, Di Lorenzo G.

Future Oncol. 2014 Jun;10(8):1353-60. doi: 10.2217/fon.14.71.

PMID:
25052746
42.

Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations?

Tartarone A, Lerose R, Lazzari C, Gregorc V, Aieta M.

Med Oncol. 2014 Aug;31(8):78. doi: 10.1007/s12032-014-0078-5. Epub 2014 Jun 24. Review.

PMID:
24958518
43.

Neuroendocrine differentiation in prostate cancer: current and emerging therapy strategies.

Conteduca V, Aieta M, Amadori D, De Giorgi U.

Crit Rev Oncol Hematol. 2014 Oct;92(1):11-24. doi: 10.1016/j.critrevonc.2014.05.008. Epub 2014 May 27. Review.

PMID:
24952997
44.

Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial.

Gregorc V, Novello S, Lazzari C, Barni S, Aieta M, Mencoboni M, Grossi F, De Pas T, de Marinis F, Bearz A, Floriani I, Torri V, Bulotta A, Cattaneo A, Grigorieva J, Tsypin M, Roder J, Doglioni C, Levra MG, Petrelli F, Foti S, Viganò M, Bachi A, Roder H.

Lancet Oncol. 2014 Jun;15(7):713-21. doi: 10.1016/S1470-2045(14)70162-7. Epub 2014 May 13.

45.

Pyrosequencing evaluation of low-frequency KRAS mutant alleles for EGF receptor therapy selection in metastatic colorectal carcinoma.

Natalicchio MI, Improta G, Zupa A, Cursio OE, Stampone E, Possidente L, Teresa Gerardi AM, Vita G, Martini M, Cassano A, Piccoli C, Romito S, Aieta M, Antonetti R, Barone C, Landriscina M.

Future Oncol. 2014 Apr;10(5):713-23. doi: 10.2217/fon.13.233.

PMID:
24799053
46.

Long-term survival in small cell lung cancer: a case report and review of the literature.

Tartarone A, Lerose R, Ardito R, Troiani L, Tedesco B, Bozza G, Cangiano R, Aieta M.

Future Oncol. 2014 Mar;10(4):523-8. doi: 10.2217/fon.13.213. Review.

PMID:
24754583
47.

Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study.

Bajetta E, Catena L, Fazio N, Pusceddu S, Biondani P, Blanco G, Ricci S, Aieta M, Pucci F, Valente M, Bianco N, Mauri CM, Spada F.

Cancer. 2014 Aug 15;120(16):2457-63. doi: 10.1002/cncr.28726. Epub 2014 Apr 18.

48.

New cancer drugs: the Italian unsatisfactory solution.

Tartarone A, Lerose R, Aieta M.

Ann Oncol. 2014 Jul;25(7):1448. doi: 10.1093/annonc/mdu151. Epub 2014 Apr 8. No abstract available.

PMID:
24718891
49.

Selected case from the Arkadi M. Rywlin International Pathology Slide Series: Leiomyomatosis peritonealis disseminata: report of 3 cases with extensive review of the literature.

Bisceglia M, Galliani CA, Pizzolitto S, Ben-Dor D, Giannatempo G, Bergoli AL, Aieta M.

Adv Anat Pathol. 2014 May;21(3):201-15. doi: 10.1097/PAP.0000000000000024.

PMID:
24713991
50.

Lymphopenia and clinical outcome of elderly patients treated with sunitinib for metastatic renal cell cancer.

De Giorgi U, Rihawi K, Aieta M, Lo Re G, Sava T, Masini C, Baldazzi V, De Vincenzo F, Camerini A, Fornarini G, Burattini L, Rosti G, Moscetti L, Chiuri VE, Luzi Fedeli S, Ferrari V, Scarpi E, Amadori D, Basso U.

J Geriatr Oncol. 2014 Apr;5(2):156-63. doi: 10.1016/j.jgo.2014.01.001. Epub 2014 Jan 22.

PMID:
24495699

Supplemental Content

Support Center